COMBINED ANTITHROMBOTIC THERAPY IN CASE OF PLANNED PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH ATRIAL FIBRILLATION IN ACTUAL CLINICAL PRACTICE
https://doi.org/10.15372/ATER20180403
Abstract
Retrospective analysis enrolled 124 patients (90 males and 34 females, mean age 67.2 ± 7.4 years) with stable coronary artery disease (CAD) and non-valvular atrial fibrillation (AF) who underwent inpatient treatment in 2016 and 2017. All patients had planned percutaneous coronary intervention (PCI) performed. As a part of combined antithrombotic therapy 104 patients received peroral anticoagulants after planned PCI. It was demonstrated that the majority of AF patients after planned PCI got triple or double antithrombotic therapy including oral anticoagulants in actual clinical practice. Significant decrease of using antiaggregants combination only in patients of this category was stated. According to clinical observation a patient with high risk of thromboembolic complications, hemorrhage, macrohematuria and planned surgical intervention due to comorbidity after PCI received double antithrombotic therapy including clopidogrel and dabigatran 110 mg twice per 24 hours. No thrombotic complications of coronary atherosclerosis, cardioembolic complications, clinically relevant bleeding were noticed in long-term postsurgical period. Modern evidential basis of advantages of double antithrombotic therapy with direct oral anticoagulants was presented. It is crucially important for patients with high risk of hemorrhagic complications.
About the Authors
N. Yu. Khorkova
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of RAS
Russian Federation
Russian Federation
A. Yu. Rychkov
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of RAS
Russian Federation
Russian Federation
A. V. Belokurova
Tyumen Cardiology Research Center, Tomsk National Research Medical Center of RAS
Russian Federation
Russian Federation
References
1. Wyse D.G., Waldo A.L., DiMarco J.P. et al. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study // Am. Heart J. 2002. Vol. 143. P. 991-1001.
2. Capodanno D., Angiolillo D.J. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions // Circ. Cardiovasc. Interv. 2014. Vol. 7. P. 113-124.
3. Kralev S., Schneider K., Lang S. et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography // PLoS ONE. 2011. Vol. 6, N 9. e24964.
4. Kirchhof P., Benussi S., Kotecha D. et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // Eur. Heart J. 2016. Vol. 37. 2893-2962.
5. Valgimigli M., Bueno H., Byrne R.A. et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. Heart J. 2017. DOI: 10.1093/eurheartj/ehx419.
6. Сулимов В.А., Голицын С.П., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и ААСХ // Рос. кардиол. журн. 2013. № 4 (102). Прил. 3. С. 1-100.
7. Li J.X., Li Y., Yan S.J. et al. Optimal antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systemic review and meta-analysis // Biomed. Rep. 2018. Vol. 8, N 2. Р. 138-147.
8. Dewilde W.J., Oirbans T., Verheuqt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial // Lancet. 2013. Vol. 381, N 9872. P. 1107-1115.
9. Gibson C.M., Mehran R., Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI // N. Engl. J. Med. 2016. Vol. 375. P. 2423-2434.
10. Cannon C. P. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation // N. Engl. J. Med. 2017. Vol. 377, N 16. P. 1513-1524.
11. Golwala H.B., Cannon C.P., Steg P.G. et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials // Eur. Heart J. 2018. Vol. 14, N 39 (19). P. 1726-1735a.
12. Steffel J., Verhamme P., Potpara T.S. et al. ESC scientific document group. The 2018 european heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation // Eur. Heart J. 2018. Vol. 21, N 39 (16). P. 1330-1393.
13. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2009. Vol. 17, N 361 (12). P. 1139-1151.
14. Patel M.R., Mahaffey K.W., Garg J. et al. ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011. Vol. 8, N. 365 (10). P. 883-91.
Review
For citations:
Khorkova N.Yu., Rychkov A.Yu., Belokurova A.V. COMBINED ANTITHROMBOTIC THERAPY IN CASE OF PLANNED PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH ATRIAL FIBRILLATION IN ACTUAL CLINICAL PRACTICE. Ateroscleroz. 2018;14(4):25-29. (In Russ.) https://doi.org/10.15372/ATER20180403
Views:
161
Email this article 